By Kate Boor Ellis
Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD).
In January 2021, two new Phase II trials have been added to the service:
- The purpose of the GRADUATION study is to evaluate the effects of once weekly administration of Gantenerumab in participants with early (prodromal to mild) AD.
- The VIVIAD study is aiming to evaluate the safety, tolerability and efficacy of PQ912 in people with mild cognitive impairment and mild dementia due to AD.
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
